Skip to main content

Table 1 Features of published cases of hematological malignancies post-germ cell tumor

From: Three distinct hematological malignancies from a single germ cell tumor: a case report

Patient age (49) Median 23 years
Range 11–35 years
Patient sex (63) Exclusively male  
Anatomic location of prior GCT (75) Exclusively mediastinal  
Histology of prior GCT (24) Variable and often mixed, including immature teratoma, yolk-sac tumour, undifferentiated histologies
Frequency of specific karyotypic abnormalities in hematological malignancy (40) Presence of i(12p) 68%
Presence of + 8 29%
Complex karyotype (≥ 3 structural abnormalities) 48%
Type of hematological malignancy (74) AML 57%
Histiocytic disorder 10%
MDS (with megakaryocytic dysplasia) 11%
Mast cell leukemia 3%
ALL 4%
Acute undifferentiated leukemia 5%
MPN 7%
Other 4%
Morphological subtype of AML (where reported) (33) M2 (Myeloblastic with maturation) 9%
M3 (Promyelocytic) 3%
M4 (Myelomonocytic) 24%
M5 (Monocytic) 9%
M6 (Erythroblastic) 6%
M7 (Megakaryoblastic) 48%
Time from GCT diagnosis to hematological malignancy (51) Median 4 months
Range 0–47 months
Survival following GCT diagnosis (35) Median 5 weeks
Maximum 44 weeks
  1. Recent case reports with allogeneic transplantation and/or novel targeted therapies have had better survival than previous case reports (> 40 weeks, n = 2), however, still none > 1 year
  2. GCT germ cell tumor, i(12p) isochromosome 12p, AML acute myeloid leukemia, MDS myelodysplastic syndrome, ALL acute lymphoblastic leukemia, MPN myeloproliferative neoplasm; M2, M3, M4, M5, M6 and M7 refer to the corresponding French-American-British morphologic classification of acute myeloid leukemia